Humanized antibodies directed against A33 antigen
AssigneeCelltech Limited
InventorsDavid John King, John Robert Adair, Raymond John Owens
Life of this patent
Estimating the term…
Abstract
A33 antigen binding proteins are described for use in the diagnosis or treatment of colorectal tumors and metastases arising therefrom. The binding protein may be a humanized A33 antibody, including complete antibody molecules, fragments thereof, and particularly, multivalent monospecific proteins comprising two, three, four or more antibodies or fragments thereof, bound to each other by a cross-linking agent. For diagnosis or therapy, the humanized A33 antibody may be linked to a reporter or effector molecule.
Claims19
A humanized antibody molecule (HAM) having specificity for the epitope recognized by the murine monoclonal antibody A33 (MAb A33), wherein said HAM comprises:
- (1) the light chain variable region comprising amino acids 28 to 135 of SEQ ID NO:
- 46;
- (2) the heavy chain variable region comprising amino acids 27 to 143 of SEQ ID NO:
- 55;
- and
- (3) remaining immunoglobulin-derived parts of the HAM being derived from a human immunoglobulin,
- said HAM being optionally conjugated to an effector or reporter molecule.
Dependencies are inferred from the claim text.